Key result
The modeled prevalence of 5q-SMA in Colombia was 0.74 per 100,000 population, with a disease burden estimated at 4,421 DALYs (8.6 DALYs/100,000), predominantly driven by premature mortality.
Why the study?
The study was conducted to estimate the disease burden of 5q-SMA in Colombia using the disability-adjusted life years metric.
Observational
5q-SMA in Colombia is associated with a significant disease burden, primarily driven by premature mortality in the 2-17 age group.
Suggests high SMA mortality burden in Colombia; leaves open prospective validation before informing policy.
OBJECTIVE: This article estimates the disease burden of 5q-SMA in Colombia by using the disability-adjusted life years (DALYs) metric. METHODS: Epidemiological data were obtained from local databases and medical literature and were adjusted in the DisMod II tool. DALYs were obtained by adding years of life lost due to premature death (YLL) and years lived with disability (YLD). RESULTS: The modeled prevalence of 5q-SMA in Colombia was 0.74 per 100,000 population. The fatality rate for all types was 14.1%. The disease burden of 5q-SMA was estimated at 4,421 DALYs (8.6 DALYs/100,000), corresponding to 4,214 (95.3%) YLLs and 207 (4.7%) YLDs. Most of the DALYs were accounted in the 2-17 age group. Of the total burden, 78% correspond to SMA type 1, 18% to type 2, and 4% to type 3. CONCLUSIONS: Although 5q-SMA is a rare disease, it is linked to a significant disease burden due to premature mortality and severe sequelae. The estimates shown in this article are important inputs to inform public policy decisions on how to ensure adequate health service provision for patients with 5q-SMA.
No takes yet. Share an insight, caveat, or question.
Gil-Rojas et al. (2023) conducted an observational in Spinal muscular atrophy linked to chromosome 5q (5q-SMA). 5q-SMA was evaluated on Disability-adjusted life years (DALYs). The modeled prevalence of 5q-SMA in Colombia was 0.74 per 100,000 population, with a disease burden estimated at 4,421 DALYs (8.6 DALYs/100,000), predominantly driven by premature mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: